Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
- Participants will undergo a radiation treatment simulation, or "mapping session" 7-14
days prior to starting radiation treatment. This is part of standard radiation
treatment.
- Participants will start radiation to the primary tumor site and to the lymph nodes and
chemotherapy in the same week. The treatment will be identical to standard
chemotherapy and radiation treatment until the 5th week. During the fifth week,
participants will undergo another radiation mapping session to prepare for the
stereotactic boost. After that, the radiation treatments to the lymph nodes will
continue but the radiation treatment to the primary cancer site will stop until the
last week (week 7). During week 7, participants will receive 2 doses of stereotactic
radiotherapy to the site of the primary tumor instead of the lower doses of
radiotherapy that they were treated with up to that point.
- Participants will be seen by the radiation oncologist at least once every week during
treatment.
- After the final dose of radiation treatment, all follow-up visits and tests are
performed in accordance with standard cancer care. Participants will see the radiation
oncologist, with or without the medical oncologist at the following time intervals: 1
week after treatment ends, 1 month after treatment ends, 2 months after treatment ends,
and then every 3 months for two years.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Maximally tolerated dose (MTD) of stereotactic boost radiotherapy
Determination of the MTD and dose-limiting toxicities of a stereotactic boost to chemoradiotherapy for stage II/III non-small cell lung cancer
2 years
Yes
Raymond H. Mak, MD
Principal Investigator
Dana-Farber Cancer Institute/Brigham and Women's Hospital
United States: Institutional Review Board
10-240
NCT01222572
December 2010
October 2012
Name | Location |
---|---|
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |